Wednesday March 13
|
|
7:30 - 9:00
|
Registration – Vanity Fair Foyer 2nd floor
Breakfast – Pall Mall, Palm Court and Vanity Fair Ballroom B
|
|
9:00 - 9:10
|
Welcome from C3i – Centre for Commercialization of Cancer Immunotherapy
Lambert Busque, Chief Medical Officer, C3i
Vanity Fair Ballroom A
|
|
Theme 1: The role of biomarkers in supporting GMP manufacturing
Moderator: Michel Rochon, Health and Science Journalist
Chair: Denis Claude Roy, CEO, CellCAN, Chief Scientific Officer, C3i
Vanity Fair Ballroom A
|
|
9:10 - 10:30
|
Characterizing products for GMP manufacturing: What, how and when?
Donna Rill, Chief Technology Officer, Triumvira Immunologics
Analytical testing: preparing for the jump from research lab to GMP manufacturing
Martin Giroux, CETC, Montréal
Raman spectroscopy analysis of cellular therapeutics for transplantation
James Piret, Professor, Department of Chemical & Biological Engineering and the Michael Smith Laboratories, University of British Columbia
|
|
10:30 - 10:50
|
Health break and exhibitors visit |
|
10:50 - 11:45
|
Regulatory expectations for cell therapy release criteria in Canada.
Dino Petrin, Senior Biologist/Evaluation Officer, Health Canada
Panelist discussion: Regulatory requirements for cell therapy release criteria
Donna Rill, Chief Technology Officer, Triumvira Immunologics
Martin Giroux, Director of operations, CETC
Dino Petrin, Senior Biologist/Evaluation Officer, Health Canada
|
|
11:45 - 13:00
|
Lunch, networking and exhibitors visit
Pall Mall, Palm Court and Vanity Fair Ballroom B
|
|
Theme 2: Clinical response to CAR Ts and other cellular therapies
Moderator: Michel Rochon, Health and Science Journalist
Chair: Jean-Sébastien Delisle, Hematologist and Principal Investigator, Hôpital Maisonneuve-Rosemont
Vanity Fair Ballroom A
|
|
13:00 - 15:00
|
Characterizing the response to cellular therapies with immunophenotyping
Jean-Sébastien Delisle, Hematologist and Principal Investigator, Hôpital Maisonneuve-Rosemont
TAC technology, its unique and novel MoA, preclinical data and considerations for biomarker analysis in our Phase I/II trial
Andreas Bader, Senior Vice President R&D, Triumvira Immunologics
Determinants of response and resistance in CAR T cell therapy
Joerg Krueger, Hematologist, Oncologist, SickKids
Improving the anti-tumor efficacy of gene-engineered T cells for the treatment of cancers
Jan Joseph Melenhorst, Adjunct Associate Professor, Pathology & Laboratory Medicine, University of Pennsylvania
|
|
15:00 - 15:20
|
Health break and exhibitors visit
|
|
Theme 3 - Companion tests and patient stratification in the era of personalized medicine
Moderator: Michel Rochon, Health and Science Journalist
Chair: David Courtman, Director, Cell Manufacturing, Biotherapeutics Manufacturing Centre, The Ottawa Hospital
Vanity Fair Ballroom A
|
|
15:20 - 16:20
|
Biomarker development for immuno-oncology applications
Raffi Tonikian, Associate Director, Immuno-oncology Biomarkers and Companion Diagnostics, Merck
Integration of companion tests in the health care system
Lambert Busque, Chief medical officer, C3i
|
|
16:20 - 16:30
|
Closing remarks of the pre-conference
Lambert Busque, Chief Medical Officer, C3i
|
|
18:30 - 21:00
|
Welcome Reception (sponsored by CCRM)
CC Lounge & Whisky Bar, 45 Front St E, Toronto, ON M5E 1B3
*Food & beverages will be provided* - bring your name badge!
Exhibition Hall
|